Updated on 17 June 2013
"We believe the court appropriately upheld our claims on cDNA, and underscored the patent eligibility of our method claims, ensuring strong intellectual property protection for our BRACAnalysis test moving forward," Peter Meldrum, president and CEO of Myriad said in a press statement.
Meanwhile, even the Association for Molecular Pathology and other supporting organisations have claimed victory in the case.
The American Civil Liberties Union that had filed the lawsuit along with the Public Patent Foundation challenging the patents called the ruling "a victory for civil liberties, scientific freedom, patients, and the future of personalized medicine."
"Today, the court struck down a major barrier to patient care and medical innovation. Myriad did not invent the BRCA genes and should not control them. Because of this ruling, patients will have greater access to genetic testing and scientists can engage in research on these genes without fear of being sued," said Sandra Park, senior staff attorney with the ACLU Women's Rights Project.
The Biotechnology Industry Organization, that has supported Myriad in this case said that the decision provided needed certainty to research-driven companies that rely on cDNA patents. However, BIO beleived that other parts of the court's decision could "unnecessarily create business uncertainty for a broader range of biotechnology inventions." ACLU on the other hand has noted that scientists can provide genetic testing without relying on cDNA.